The Ledger

Hospital AI tools found $942 million worth of conditions to code. Insurers say the care that should have followed those codes did not. The Blue Cross Blue Shield Association published an analysis September 24, 2026 finding that hospital use of AI coding tools added an estimated $942 million to what Blue Cross and Blue Shield companies paid from 2023 through 2025. Secondary diagnoses, conditions that AI identifies when it scans patient records and lab results for billable codes, drove approximately $650 million of the total; those codes pushed more than 55,000 inpatient stays into higher-paying diagnosis-related groups at roughly $11,900 per case. More than 60 percent of hospital systems now use AI-assisted coding. In the case the association analyzed most closely, major bowel surgery claims, the number of patients coded with secondary anemia diagnoses rose sharply while blood transfusions, the treatment typically required for such a diagnosis, did not. “The disconnect between diagnoses and treatment suggests that AI is identifying more billable conditions, not sicker patients,” said Luke Chalker, BCBSA’s senior vice president. The association acknowledged the findings do not conclusively establish improper billing and that higher diagnosis rates could reflect genuinely improved documentation in some cases, but the $942 million figure gives payers a public anchor for contract and audit pressure on AI coding practices. Confidence: High. Source: BCBSA Hospital Coding Intensity Analysis, September 24, 2026, Blue Cross Blue Shield Association

Cigna just put OpenAI’s frontier reasoning models directly inside its oncology nurses’ clinical workflows, the first known deployment of a major AI model inside a US managed care company’s clinical operations. The Cigna Group and OpenAI announced a collaboration September 25, 2026 to embed OpenAI’s frontier reasoning capabilities into Cigna’s clinical and consumer-facing systems, starting with cancer patients. Oncology nurses and case managers at Cigna Healthcare and Accredo Specialty Pharmacy, the company’s specialty pharmacy unit, will receive AI tools that unite clinical, pharmacy, behavioral health, and benefits data, with the stated goal of identifying emerging patient needs earlier and improving coordination across a complex treatment journey. The announcement discloses no financial terms, no scale of patient enrollment, and no specific OpenAI model by name. The strategic significance is placement: OpenAI’s reasoning is now inside the workflow of a managed care organization, not as a consumer product or a back-office tool, but as part of the clinical-management layer that shapes how cancer patients get supported between physician visits. Confidence: Medium-High. Primary source not directly retrieved this run; confirmed via multiple trade outlets reporting the companies’ own September 25 announcement. Sources: The Cigna Group and OpenAI Collaborate to Advance Care for Complex Conditions, Repertoire Magazine sourcing Cigna Group newsroom, Cigna Group, OpenAI Partner to Support Patients With Complex Conditions, Modern Healthcare

Oura’s IPO is four times covered and has a $400 million cornerstone commitment from Eli Lilly and Dragoneer, with pricing set for next week. Bloomberg reported September 25, 2026 that orders for the Oura Inc. Nasdaq IPO total about four times the amount of stock on offer, with pricing expected the week of September 28 and the first trade expected September 30 under ticker OURA. Eli Lilly and Dragoneer Investment Group have committed approximately $400 million combined as cornerstone investors; Eli Lilly’s position is notable given its existing partnership with Oura on biometric tracking and its publicly stated interest in using continuous health data to monitor GLP-1 drug adherence and outcomes. As this newsletter reported September 22, Oura’s amended S-1 values the company at approximately $14.1 billion at the midpoint of its $40 to $44 per-share price range, and the company expects to end its fiscal year September 30 with roughly 5.7 million paying members and 240.5 million dollars in membership revenue at an 89 percent gross margin. The four-times oversubscription confirms strong investor demand for the health-wearables category, though 36.5 million of the 50 million shares on offer remain secondary shares from existing investors, with early backer Forerunner Ventures alone selling approximately 28.7 million shares. Confidence: High on the Bloomberg oversubscription figure and the combined cornerstone total drawn from the prospectus; Medium on the strategic inference about Lilly’s GLP-1 rationale, drawn from public partnership disclosures rather than Lilly’s stated rationale for the purchase. Sources: Smart Ring Maker Oura’s IPO Is About Four Times Oversubscribed, Bloomberg, Oura Inc., Form S-1/A, SEC EDGAR

Abridge won a seat on the VA’s $775.7 million ambient AI enterprise contract, the federal government’s largest-ever procurement vehicle for ambient clinical AI and the first to cover a 1,380-facility, 9-million-veteran healthcare system. The Department of Veterans Affairs selected Abridge September 22, 2026 for a five-year, multiple-award indefinite-delivery indefinite-quantity contract with a ceiling of $775.72 million across all eligible vendors, through which individual VA medical centers and regional Veterans Integrated Services Networks can issue task orders for ambient AI services. Abridge is already operational at more than 75 VA medical centers following a nationwide pilot and its platform works across both of the VA’s current EHR systems, VistA/CPRS and the Federal EHR, meaning it remains in place through the VA’s ongoing and troubled EHR transition. The $775.72 million ceiling is shared across all contract holders, not committed solely to Abridge, but the vehicle represents the federal government’s formal determination that ambient AI is ready for enterprise deployment at population scale, setting a benchmark that commercial health systems and payers will face in vendor negotiations and board-level AI investment decisions. Confidence: High. Source: Abridge Selected to Bring Ambient AI to Veteran Care Nationwide Through the VA Enterprise Contract, Abridge

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
VA enterprise ambient AI contract (Abridge seat)	Abridge (distributed through partner)	Ambient clinical AI, federal healthcare	$775.72 million ceiling across all eligible vendors over 5 years; awarded September 22, 2026	Abridge press release
Oura Inc. (50 million shares; pricing expected September 29)	Public markets, Nasdaq: OURA	Consumer health wearables	Expected $2.2 billion total offering; Eli Lilly and Dragoneer committed approximately $400 million combined as cornerstone investors; midpoint valuation approximately $14.1 billion	Bloomberg
Agilex Biolabs (bioanalytical lab, Adelaide, Australia)	Novotech CRO (backed by TPG)	Clinical research, bioanalytical services	$160 million enterprise value; announced September 25, 2026, subject to regulatory clearances	Novotech CRO press release
Independence Health System (5 hospitals, western Pennsylvania)	WVU Health System (WVU Medicine)	Nonprofit hospital affiliation	$800 million in planned investment over 5 years; deal signed June 2026, close expected late September or early October 2026; close not confirmed in a primary source as of this run	WVU Medicine definitive agreement, WVU Medicine newsroom

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours. The MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in active discovery, with the bellwether trial still set for December 7, 2027. A frontier check on the dental service organization sector (I-1 branch), last covered in this newsletter July 27, found that Guardian Dentistry Partners had entered a majority acquisition of Select Dental Management, a 38-location dental group in eight states plus Washington D.C., in a deal announced July 15 with a Q3 2026 closing target financed by TPG Twin Brook, Morgan Stanley Private Credit, and Prudential; the close had not been confirmed in a primary public source as of this run and will be revisited when a closing announcement lands. A frontier check on the clinical trials supply chain (L-1 branch) surfaced Novotech’s $160 million acquisition of Agilex Biolabs, included in the Deal Sheet above; Novotech is TPG-backed and the deal gives it a specialist bioanalytical footprint in Australia serving US and global pharma sponsors. No new recurring source requiring addition to the source stack was identified.